Evidence map›Paper›PMID 33666358›Full record

ReviewPigment cell & melanoma research2021

Pharmacologic manipulation of skin pigmentation.

Gabriel H Kindl, John A D'Orazio

Open access · bronzeAbstract readReview
In one paragraph

Review in Pigment cell & melanoma research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Antimelanogenesis Effects of Theasinensin A.International journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Gabriel H KindlThe University of Kentucky College of Medicine, University of Kentucky, Lexington, KY, USA.
John A D'OrazioThe University of Kentucky College of Medicine, University of Kentucky, Lexington, KY, USA.ORCID 0000-0003-1008-6234
University of Kentucky · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
Pilot Project ProgramP30ES026529 · NIEHS · UNIVERSITY OF KENTUCKY · PI Jason Unrine · 2017 to 2026
$15.4M
The role of Mc1r in melanocytic UV-induced DNA damage and repair responsesR01CA131075 · NCI · UNIVERSITY OF KENTUCKY · PI D'ORAZIO, JOHN A · 2010 to 2020
$3.3M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA131075NIEHS NIH HHS P30 ES026529
6 · The paper itself

Abstract

Skin complexion is among the most recognizable phenotypes between individuals and is mainly determined by the amount and type of melanin pigment deposited in the epidermis. Persons with dark skin complexion have more of a brown/black pigment known as eumelanin in their epidermis whereas those with fair skin complexions have less. Epidermal eumelanin acts as a natural sunblock by preventing incoming UV photons from penetrating into the skin and therefore protects against UV mutagenesis. By understanding the signaling pathways and regulation of pigmentation, strategies can be developed to manipulate skin pigmentation to improve UV resistance and to diminish skin cancer risk.

Indexed as

Pharmaceutical PreparationsAnimalsEnzyme InhibitorsHumansMelaninsSkin PigmentationTranslational Research, BiomedicalEnzyme InhibitorsMelaninsPharmaceutical PreparationscAMPmelaninmelanocortin 1 receptormelanocytepigmentation

Identifiers

PMID33666358
PMCPMC8277713
OpenAlexW3134141858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.